

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED

BALANCE SHEET

3/31/2017

ASSETS

Current	
Cash	1,546
Accounts Receivable	-
Fixed Asset	-
TOTAL ASSETS	<u>1,546</u>

LIABILITIES

Current	
Loan	10,000
Sales Tax Payable	
Notes Payable	171,368
Total Liabilities	<u>181,368</u>

STOCKHOLDERS' EQUITY

SHARE CAPITAL	
Common shares, 5,500,000,000 authorized, par value \$0.0001 - Issued and outstanding, March 31, 2016 - 4,674,999,733	435,000
Preferred shares, 10,000,000 authorized Issued and outstanding, March 31, 2016 - 10,000,000	1,000
Accumulated Deficit	(615,822)
Shareholders net gain (loss)	<u>(179,822)</u>
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	<u>1,546</u>

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED

3/31/2017

STATEMENTS OF EARNINGS

REVENUE

Income	-
Cost of Sales	<u>(83)</u>
Gross Margin	<u>83</u>

OPERATING EXPENSES

Selling, general and administrative	4,780
Total Operating Expenses	<u>4,780</u>

NET GAIN (LOSS) (4,780)

Weighted Average Number of Common Shares	4,349,999,733
Net Loss Per Share - Basic and Fully Diluted	(0.00)

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss	(4,780.00)
Stock issued for services rendered	-
Stock issued for cash	-
Changes in assets and liabilities	-
Accounts payable	<u>-</u>

NET CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES (4,780)

CASH FLOWS FROM FINANCING ACTIVITIES

Advances by(to) shareholder	-
Share capital issued	-

NET CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES

Cash and Cash Equivalents - beginning of quarter	3,577
Cash and Cash Equivalents - end of quarter	1,546
Net Change In Cash	5,123

NOUVEAU LIFE PHARMACEUTICALS, INC.
CONSOLIDATED FINANCIALS
UNAUDITED

3/31/2017

STOCKHOLDERS' EQUITY

	Common Shares	Stock Amount	Additional Paid In Capital
	<hr/>		
Balance December 31, 2016	4,349,999,733	435,000	
Stock issued for services	-		
Stock issued for cash	200,000,000	20,000	
Stock issued for acquisition	125,000,000	12,500	
Balance March 31, 2017	4,674,999,733	467,500	